p53-Independent Down-Regulation of Mdm2 in Human Cancer Cells Treated with Adriamycin

By Ma Y.   Yuan R.   Meng Q.   Goldberg I.D.   Rosen E.M.   Fan S.  

Molecular Cell Biology Research Communications, Vol. 3, Iss. 2, 2000-02 ,pp. : 122-128

Academic Press

Access to resources Recommend Favorite

Specific down-regulation of an engineered human cyclin D1 promoter by a novel DNA-binding ligand in intact cells

By Laurance M.E.   Starr D.B.   Michelotti E.F.   Cheung E.   Gonzalez C.   Tam A.W.   Deikman J.   Edwards C.A.   Bardwell A.J.  

Nucleic Acids Research, Vol. 29, Iss. 3, 2001-02 ,pp. : 652-661

Oxford University Press

Access to resources Recommend Favorite

Repression of Cyclin B1 Expression after Treatment with Adriamycin, but Not Cisplatin in Human Lung Cancer A549 Cells

By Dan S.   Yamori T.  

Biochemical and Biophysical Research Communications, Vol. 280, Iss. 3, 2001-01 ,pp. : 861-867

Elsevier

Access to resources Recommend Favorite

Down-regulation of MDM2 and activation of p53 in human cancer cells by antisense 9-aminoacridine–PNA (peptide nucleic acid) conjugates

By Shiraishi Takehiko   Nielsen Peter E.  

Nucleic Acids Research, Vol. 32, Iss. 16, 2004-01 ,pp. : 4893-4902

Oxford University Press

Access to resources Recommend Favorite

Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage

By Wilson Peter M.  

Nucleic Acids Research, Vol. 37, Iss. 1, 2009-01 ,pp. : 78-95

Oxford University Press

Access to resources Recommend Favorite